Patents Represented by Attorney Millennium Pharmaceuticals, Inc.
  • Patent number: 6979564
    Abstract: The invention provides isolated nucleic acids molecules, designated 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, which encode novel fucosyltransferase, seven transmembrane receptor, or RhoGAP family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 80090, 52874, 52880, 63497, or 33425 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an 80090, 52874, 52880, 63497, or 33425 gene has been introduced or disrupted. The invention still further provides isolated 80090, 52874, 52880, 63497, or 33425 proteins, fusion proteins, antigenic peptides and anti-80090, 52874, 52880, 63497, or 33425 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 19, 2001
    Date of Patent: December 27, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Maria A. Glucksmann, Rachel Meyers
  • Patent number: 6977240
    Abstract: The present invention relates to the discovery, identification and characterization of nucleotides that encode Ob receptor (ObR), a receptor protein that participates in mammalian body weight regulation. The invention encompasses obR nucleotides, host cell expression systems, ObR proteins, fusion proteins, polypeptides and peptides, antibodies to the receptor, transgenic animals that express an obR transgene, or recombinant knock-out animals that do not express the ObR, antagonists and agonists of the receptor, and other compounds that modulate obR gene expression or ObR activity that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of body weight disorders, including but not limited to obesity, cachexia and anorexia.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: December 20, 2005
    Assignee: Millenium Pharmaceuticals, Inc.
    Inventors: Louis A. Tartaglia, Robert I. Tepper, Janice A. Culpepper, David W. White
  • Patent number: 6972187
    Abstract: The invention provides isolated nucleic acids molecules, designated OAT5 nucleic acid molecules, which encode organic anion transporters. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing OAT5 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a OAT5 gene has been introduced or disrupted. The invention still further provides isolated OAT5 polypeptides, fusion polypeptides, antigenic peptides and anti-OAT5 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: December 6, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rory A. J. Curtis, Maria Alexandra Glucksmann, Rachel E. Meyers
  • Patent number: 6962811
    Abstract: The invention provides isolated nucleic acids molecules, designated 14715 nucleic acid molecules, which encode novel fringe family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14715 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14715 gene has been introduced or disrupted. The invention still further provides isolated 14715 proteins, fusion proteins, antigenic peptides and anti-14715 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: November 8, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Karen L. Anderson
  • Patent number: 6960651
    Abstract: The invention provides isolated nucleic acids encoding a variety of proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: November 1, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Susan J. Kirst, Douglas A. Holtzman, Christopher C. Fraser, John D. Sharp, Thomas S. Barnes
  • Patent number: 6953778
    Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: October 11, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Joseph M. Carroll
  • Patent number: 6953657
    Abstract: Novel CARD-7 and CARD-8 polypeptides, proteins, and nucleic acid molecules are disclosed. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: November 27, 2001
    Date of Patent: October 11, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • Patent number: 6953874
    Abstract: The present invention relates to nonhuman transgenic animals in which the GP V gene has been modified. The invention is also useful for identifying agents that modulate the biological functions of GP V, including the screening and identification of potential therapeutic agents.
    Type: Grant
    Filed: February 5, 2001
    Date of Patent: October 11, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Vanitha Ramakrishnan, David R. Phillips
  • Patent number: 6953682
    Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 7, 2002
    Date of Patent: October 11, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Miyoung Chun, Maria Alexandra Glucksmann, Rosana Kapeller-Libermann, Rachel E. Meyers
  • Patent number: 6953672
    Abstract: Disclosed is a yeast cell whose genetic complement includes an inactive allele of the yeast CDC7 gene, a first nucleic acid that encodes a mammalian Cdc7 protein, and a second nucleic acid that encodes a mammalian Dbf4 protein. The yeast cell is dependent on the mammalian Cdc7 and Dbf4 proteins for viability. The yeast cell can be used to identify potential anti-proliferative agents by virtue of their inhibition of the mammalian Cdc7 and Dbf4 proteins. In some embodiments, a control yeast cell which does not depend on Cdc7 for viability is used in a secondary screen.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: October 11, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Benjamin Stone Amidon, Christine Ellen Bulawa
  • Patent number: 6946274
    Abstract: The invention provides isolated nucleic acids molecules, designated 13245 nucleic acid molecules, which encode a novel myotonic dystrophy type protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 13245 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 13245 gene has been introduced or disrupted. The invention still further provides isolated 13245 proteins, fusion proteins, antigenic peptides and anti-13245 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: September 20, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rosana Kapeller-Libermann
  • Patent number: 6942984
    Abstract: Novel CARD-12 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-12 proteins, the invention further provides CARD-12, fusion proteins, antigenic peptides and anti-CARD-12 antibodies. The invention also provides CARD-12 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-12 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: September 13, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • Patent number: 6939698
    Abstract: The invention provides isolated nucleic acids molecules, designated 33945 nucleic acid molecules, which encode novel glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 33945 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 33945 gene has been introduced or disrupted. The invention still further provides isolated 33945 proteins, fusion proteins, antigenic peptides and anti-33945 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: February 12, 2002
    Date of Patent: September 6, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Peter J. Olandt, Rachel E. Meyers, Katherine M. Galvin
  • Patent number: 6936690
    Abstract: Novel CARD-14 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-14 proteins, the invention further provides CARD-14 fusion proteins, antigenic peptides and anti-CARD-14 antibodies. The invention also provides CARD-14 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-14 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: August 30, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: John Bertin
  • Patent number: 6933115
    Abstract: The invention concerns the human gene encoding GLUTX, a glucose transporter. GLUTX nucleic acid and polypeptides, as well as molecules which increase or decrease expression or activity of GLUTX, are useful in the diagnosis and treatment of disorders associated with aberrant hexose transport.
    Type: Grant
    Filed: October 18, 2001
    Date of Patent: August 23, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Louis A. Tartaglia, Xun Weng
  • Patent number: 6929938
    Abstract: The invention provides isolated nucleic acids molecules, designated 25501 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25501 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25501 gene has been introduced or disrupted. The invention still further provides isolated 25501 proteins, fusion proteins, antigenic peptides and anti-25501 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: August 12, 2002
    Date of Patent: August 16, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Rachel E. Meyers
  • Patent number: 6911335
    Abstract: The invention provides isolated nucleic acids molecules, designated 57316 or 33338 nucleic acid molecules, which encode ubiquitin carboxyl terminal hydrolase proteins. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57316 or 33338 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 57316 or 33338 gene has been introduced or disrupted. The invention still further provides isolated 57316 or 33338 proteins, fusion proteins, antigenic peptides and anti-57316 or 33338 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: June 28, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Rajasekhar Bandaru
  • Patent number: 6911317
    Abstract: The invention provides isolated nucleic acids molecules, designated 2150 nucleic acid molecules, which encode novel protein kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 2150 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 2150 gene has been introduced or disrupted. The invention still further provides isolated 2150 proteins, fusion proteins, antigenic peptides and anti-2150 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 27, 2002
    Date of Patent: June 28, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rachel E. Meyers, Jose M. Lora
  • Patent number: 6900044
    Abstract: The invention provides isolated nucleic acids molecules, designated 68999 nucleic acid molecules, which encode ubiquitin carboxyl-terminal hydrolase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 68999 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 68999 gene has been introduced or disrupted. The invention still further provides isolated 68999 proteins, fusion proteins, antigenic peptides and anti-68999 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: May 31, 2005
    Assignee: Millennium Pharmaceutical, Inc.
    Inventor: Rosana Kapeller-Libermann
  • Patent number: 6900303
    Abstract: The invention provides isolated nucleic acids molecules, designated 57658 nucleic acid molecules, which encode novel uridine kinase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 57658 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 57658 gene has been introduced or disrupted. The invention still further provides isolated 57658 proteins, fusion proteins, antigenic peptides and anti-57658 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: June 28, 2001
    Date of Patent: May 31, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Maria A. Glucksmann